RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.
The conversation discusses the effectiveness and authenticity of RU58841 purchased from Amazon, with some users suggesting buying from reputable sources like Anagen Inc. Others recommend using oral finasteride instead of RU58841 due to concerns about product legitimacy.
A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.
The user is experiencing hair loss and is using finasteride while addressing low ferritin and copper levels. They are concerned about continued hair shedding and are advised to correct vitamin deficiencies and wait for finasteride results after 12 months.
The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
A user is experiencing hair thinning and is using a peptide with oleanic acid as a DHT blocker, along with minoxidil, while waiting for topical finasteride. They plan to use a combination of minoxidil, finasteride, dermastamp, ketoconazole, and scalp massages, but are advised to stick to proven treatments like finasteride and minoxidil.
A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
The user shared progress after two months of using finasteride, serioxyl, and NOOANCE casque Pro for alopecia. They are documenting their hair loss treatment journey.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
A user noticed deeper facial wrinkles since starting oral minoxidil in February 2023 and is concerned about its effects on collagen production. Other factors include past accutane use, high stress, poor sleep, and COVID-19.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.
The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
A 22-year-old used oral finasteride from Costco and topical Kirkland minoxidil for 4-5 months to treat hair loss, resulting in significant hair regrowth and restored confidence. The "big 3" refers to minoxidil, finasteride, and microneedling as hair loss treatments.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.
The user experienced significant hair regrowth after 2.5 years of using Minoxidil 5% and hormone replacement therapy (HRT) with Lupron, despite initial scalp irritation. Finasteride was ineffective for them.
The conversation is about a hair loss treatment regimen that includes finasteride, dutasteride, oral minoxidil, Dermapen, quercetin, N-acetyl L-cysteine, biotin, millet seed extract, MSM, OPC, green tea extract, high-dose vitamins B1-B12, boron, and silica. The user is seeking advice on additional treatments.
OP is using 5% minoxidil and a foligain supplement for hair loss, with blood test results showing high cortisol levels. OP is considering starting finasteride, while another user shares their experience with finasteride and hair loss challenges due to malabsorption issues.
The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.
RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.
The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.
KOSHINE826 is a new anti-hair loss and hair growth solution that claims to effectively control oil, reduce hair fall, and promote real hair growth. It targets androgenetic alopecia by inhibiting DHT and has shown promising results in clinical trials.